Minolexin and its place in standard therapy for acne vulgaris

Abstract

Propionebacteria acne react with congenital immunity markers - Toll-like (TLR) and protease-activated (PAR) receptors. In the epidermis TLR is expressed on epitheliocytes, keratinocytes, Langerhans ’ cells, macrophages, monocytes, and granulocytes, and is directly involved in the formation of antibacterial response. The role of PAR in the pathogenesis of acne consists in induction and stimulation of the unfolding inflammatory process via stimulation of expression of IL-1a, tumor necrosis factor-a, human b-defensin 2 (hBD2), matrix metalloproteinasesmMP-1, MMP-2, MMP-3, MMP-9, andMMP-13. Hence, P. acne is involved in many processes in the pathogenesis of acne vulgaris, including inflammation, hyperkeratosis, and excessive production of the sebum, this necessitating its eradication - an important component of combined therapy. Minolexin® (minocyclin) is a highly effective drug for therapy of medium-severe and severe forms of acne vulgaris. The drug is included in the European recommendations for therapy. The drug is characterized by a pronounced bacteriostatic effect and is highly lipophilic, rapidly penetrates through the bacterial lipid layer, and intensely cumulates in the sebaceous glands.

Keywords

acne vulgaris / pathogenesis / TLR / PAR / therapy / minocyclin

RIGHTS & PERMISSIONS

Eco-Vector